OncoSil Medical (ASX:OSL) said the German Institute for the Hospital Remuneration System authorized 120 German hospitals to negotiate fees for the OncoSil device classification under the NUB innovation funding program with statutory health insurance companies as part of annual budget negotiations, according to a Tuesday filing with the Australian bourse.
OncoSil received a "Positive Status 1" classification under the innovation funding program in 2021, the filing said.
In October 2024, the German Federal Joint Committee approved a directive for testing a new treatment method for pancreatic cancer, and in January, approval from the Ministry of Health was received, per the filing.
The Oncosil device is a targetted treatment directly to locally advanced pancreatic cancer delivered via injection and is used in combination with chemotherapy.
Shares surged 40% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.